Prostate cancer prevention: What do we know now, and when will we know more?

Ian M. Thompson; Joseph Basler; Deborah Hensley; Dendra Von Merveldt; Carol A. Jenkins; Betsy Higgins; Robin Leach; Dean Troyer; Brad Pollock

doi:10.3816/CGC.2003.n.002

Prostate cancer prevention: What do we know now, and when will we know more?

Ian M. Thompson, Joseph Basler, Deborah Hensley, Dendra Von Merveldt, Carol A. Jenkins, Betsy Higgins, Robin Leach, Dean Troyer, Brad Pollock

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

Original language	English (US)
Pages (from-to)	215-220
Number of pages	6
Journal	Clinical Prostate Cancer
Volume	1
Issue number	4
DOIs	https://doi.org/10.3816/CGC.2003.n.002
State	Published - Mar 2003

Keywords

Biomarker
Early detection
Hormonal agents
Selenium
Vitamin E

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.3816/CGC.2003.n.002

Cite this

@article{ae35b2787b6e41b39c4dc075bfbe886d,

title = "Prostate cancer prevention: What do we know now, and when will we know more?",

abstract = "Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.",

keywords = "Biomarker, Early detection, Hormonal agents, Selenium, Vitamin E",

author = "Thompson, {Ian M.} and Joseph Basler and Deborah Hensley and {Von Merveldt}, Dendra and Jenkins, {Carol A.} and Betsy Higgins and Robin Leach and Dean Troyer and Brad Pollock",

year = "2003",

month = mar,

doi = "10.3816/CGC.2003.n.002",

language = "English (US)",

volume = "1",

pages = "215--220",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Prostate cancer prevention

T2 - What do we know now, and when will we know more?

AU - Thompson, Ian M.

AU - Basler, Joseph

AU - Hensley, Deborah

AU - Von Merveldt, Dendra

AU - Jenkins, Carol A.

AU - Higgins, Betsy

AU - Leach, Robin

AU - Troyer, Dean

AU - Pollock, Brad

PY - 2003/3

Y1 - 2003/3

N2 - Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

AB - Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

KW - Biomarker

KW - Early detection

KW - Hormonal agents

KW - Selenium

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=0041970199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041970199&partnerID=8YFLogxK

U2 - 10.3816/CGC.2003.n.002

DO - 10.3816/CGC.2003.n.002

M3 - Review article

C2 - 15040879

AN - SCOPUS:0041970199

VL - 1

SP - 215

EP - 220

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -

Prostate cancer prevention: What do we know now, and when will we know more?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this